SCHEMBL1006702

SCHEMBL1006702

[CH2][C]C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL47739 0.67
SCHEMBL277083 0.67
SCHEMBL5719204 0.67
SCHEMBL4162328 0.63 ALDH1A1 (0.36)
SCHEMBL18641296 0.63
SCHEMBL27750855 0.63
SCHEMBL27952649 0.63
Hydrochloric Acid SCHEMBL27782124 0.63
SCHEMBL4119428 0.59
SCHEMBL3666143 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220009946-A1 FUSED HETEROCYCLIC BENZODIAZEPINE DERIVATIVES AND USES THEREOF INTOCELL, INC. (KR) 2022-01-13 US disclosed
WO-2020167566-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOL USE DISORDERS THE ROCKEFELLER UNIVERSITY (US) 2020-08-20 WO disclosed
US-10711037-B2 Chemical and biochemical adducts as biomarkers for organophosphate exposure HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2020-07-14 US disclosed
US-10570088-B2 Blood brain barrier-penetrating oximes for cholinesterase reactivation HUMAN BIOMOLECULAR RES FOUNDATION (US) 2020-02-25 US disclosed
US-20170349538-A1 Blood Brain Barrier-Penetrating Oximes for Cholinesterase Reactivation Human BioMolecular Research Foundation (US) 2017-12-07 US disclosed
US-9751831-B2 Blood brain barrier-penetrating oximes for cholistenerases reactivation HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2017-09-05 US disclosed
US-20170101441-A1 CHEMICAL AND BIOCHEMICAL ADDUCTS AS BIOMARKERS FOR ORGANOPHOSPHATE EXPOSURE Human BioMolecular Research Foundation (US) 2017-04-13 US disclosed
US-20170097334-A1 SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-04-06 US disclosed
US-9549991-B2 Chemical and biochemical adducts as biomarkers for organophosphate exposure HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2017-01-24 US disclosed
EP-2276510-B1 Chemical and biochemical adducts as biomarkers for organophosphate exposure HUMAN BIOMOLECULAR RES INST (US) 2016-07-06 EP disclosed
US-20090054312-A1 SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2009-02-26 US disclosed
WO-2008153760-A1 INHIBITORS OF THAPSIGARGIN-INDUCED CELL DEATH BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2008-12-18 WO disclosed
WO-2008118626-A9 INHIBITORS OF JNK AND METHODS FOR IDENTIFYING INHIBITORS OF JNK BURNHAM INST MEDICAL RESEARCH (US) 2008-12-18 WO disclosed
US-20080293699-A1 Inhibitors of thapsigargin-induced cell death BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2008-11-27 US disclosed
WO-2008118626-A2 INHIBITORS OF JNK AND METHODS FOR IDENTIFYING INHIBITORS OF JNK BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2008-10-02 WO disclosed
US-20080206287-A1 Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands REED JOHN C 2008-08-28 US disclosed
US-20080166378-A1 DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR THE BURNHAM INSTITUTE 2008-07-10 US disclosed
WO-2008070347-A2 BETULIN-PEPTIDE CONJUGATES REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2008-06-12 WO disclosed
WO-2008036244-A1 USE OF CYCLOSPORIN A TO SENSITIZE RESISTANT CANCER CELLS TO DEATH RECEPTOR LIGANDS THE BURHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2008-03-27 WO disclosed
US-20070203236-A1 NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE UNITED STATES GOVERNMENT 2007-08-30 US disclosed